Visual Function Changes After Intraocular Pressure Reduction
Completed
University of Sao Paulo
N/A
2005-09-01
During the glaucomatous disease process, subpopulations of cells may be dead, damaged or
healthy. Visual function changes could be observed due to a recovering of the suffering
ganglion cells after the intraocular pressure reduction. This study aims at evaluating the
correlation between intraocular pressure reduction and visual function changes in glaucoma
patients after using antiglaucoma medications.
Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)
Completed
Bp Consulting, Inc
Phase 4
2008-06-01
To assess the additional benefit of common adjunctive classes on the diurnal IOP curve in
patients assessed as needing additional treatment to reach target intraocular pressure (IOP).
To demonstrate superiority of IOP control with Istalol 0.5% QD compared to Brimonidine
Tartrate 0.2% BID as adjunctive therapy in adults with uncontrolled IOP's (determined by P.I.
based on target pressures) currently treated with Latanoprost 0.05% in the study eye(s).
An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects
Completed
Allergan
Phase 4
2008-12-01
A three-month evaluation comparing the safety and efficacy of a fixed combination of 0.2%
brimonidine tartrate/0.5% timolol maleate with that of latanoprost 0.005%, a prostaglandin
analogue in glaucoma or ocular hypertension subjects
Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow
Completed
Allergan
Phase 4
2008-12-01
A 10 week evaluation, crossover design study including a 3 week washout period between
treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate
0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol
maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
